Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, and Preliminary Anti-tumor Activity of TNG462 as a Single Agent and in Combination in Patients With MTAP-deleted Advanced or Metastatic Solid Tumors

NCT05732831 is registered in ClinicalTrials.gov with Tango Therapeutics, Inc. as lead sponsor.

NCT NCT05732831
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05732831 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, and Preliminary Anti-tumor Activity of TNG462 as a Single Agent and in Combination in Patients With MTAP-deleted Advanced or Metastatic Solid Tumors
Lead sponsor
Tango Therapeutics, Inc.
Phase
Phase 1/2
Overall status
Recruiting
Start date
May 26, 2023
Completion date
June 30, 2028
Enrollment
225 (estimated)
Sites
26

Conditions

As the registry lists them; a condition with its own page is linked.

locally advanced solid tumor